A Federation of American Scientists online paper says FDA, other federal research agencies, and Congress should take steps to increase surrogate endpoint transparency by providing information on the endpoints’ strength of evidence of clinical benefit.
Human Drugs
Biotech Leaders Support Access to Mifepristone
A letter from dozens of biotechnology industry executives and investors urges FDA commissioner Marty Makary to reject efforts to restrict access to the abortion medication mifepristone.
